October 2, 2026
“Earlier this week, President Donald Trump said CFTC Chair Mike Selig is working to bring the Hyperliquid exchange into the U.S. in a fully compliant way, coinciding with strong interest in both the HYPE token and Hyperliquid Strategies, which holds… Continue Reading…
September 30, 2026
“Netflix (NASDAQ: NFLX) stock is down 43% from its high, something that has happened only twice in the last 15 years… If history is any indication, a forward P/E ratio of 21 is probably not a bottom signal for Netflix stock…”… Continue Reading…
September 23, 2026
“… Amid its 58% market share, revenue in the second quarter of 2026 rose by 257% yearly, while its net income is up 1,242% to nearly 94 trillion won ($66 billion). Demand is so high that some investors seem to have… Continue Reading…
September 23, 2026
“Investing.com — Nebius Group’s stock surged 34% on August 12 after the AI cloud company posted second-quarter revenue of $582.3 million, up 454% year-over-year and ahead of analyst estimates of $572.75 million compiled by LSEG. The blowout results did not… Continue Reading…
August 18, 2026
“If you had the foresight to buy Sandisk (NASDAQ: SNDK) stock at the start of 2026, you’re probably a happy investor. It’s up a jaw-dropping 580% at the time of this writing, easily outperforming nearly every other stock in the market. However,… Continue Reading…
August 3, 2026
“IBM stock tanked after the company released preliminary second-quarter results that fell short of expectations. CEO Arvind Krishna blamed the shortfall on weakness in the software and infrastructure business, as clients shifted spending toward hardware purchases such as memory chips.… Continue Reading…
July 31, 2026
“Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology company announced positive topline results from the 36-week Part B analysis of its SIGNAL-AA Phase 2a study evaluating bempikibart for the treatment of severe and very severe alopecia… Continue Reading…
July 28, 2026
“AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition. Shares slumped and were on track for the worst day in over six years. Jefferies analysts said the… Continue Reading…
July 22, 2026
“Fourth-quarter revenue skyrocketed 133% year-over-year to $641.6 million, propelled by strong defense demand. Adjusted quarterly earnings reached $1.84 per share, comfortably beating the consensus analyst estimate of $1.47 per share. The company’s funded backlog climbed to $1.2 billion, up from… Continue Reading…
Recent Comments